Clinically Approved Drugs Inhibit the Staphylococcus aureus Multidrug NorA Efflux Pump and Reduce Biofilm Formation

Clinically Approved Drugs Inhibit the Staphylococcus aureus Multidrug NorA Efflux Pump and Reduce Biofilm Formation

Staphylococcus aureus has acquired resistance to antibiotics since their first use. The S. aureus protein NorA, an efflux pump belonging to the major facilitator superfamily (MFS), contributes to resistance to fluoroquinolones (e.g., ciprofloxacin), biocides, dyes, quaternary ammonium compounds, and...

Full description

Bibliographic Details
Main Authors: Saskia Zimmermann, Mareike Klinger-Strobel, Jürgen A. Bohnert, Sindy Wendler, Jürgen Rödel, Mathias W. Pletz, Bettina Löffler, Lorena Tuchscherr
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Microbiology
Subjects:
multidrug resistance
biofilm
NorA
S. aureus
clinical drugs
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2019.02762/full

Internet

https://www.frontiersin.org/article/10.3389/fmicb.2019.02762/full

Similar Items